NasdaqGS:OLMABiotechs
Olema Pharmaceuticals (OLMA): Evaluating Valuation After Surge Linked to Roche’s Positive Breast Cancer Drug Results
Olema Pharmaceuticals (OLMA) shares jumped after Roche reported positive Phase 3 data for giredestrant, a breast cancer treatment in the same class as Olema’s investigational drug palazestrant. This announcement quickly drew market attention.
See our latest analysis for Olema Pharmaceuticals.
Momentum around Olema Pharmaceuticals has exploded, with the share price up 141% over the past week and a striking 250% in the past three months. Confidence is high thanks to Roche’s positive trial...